More articles from Editorial

  • SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now
    Jonathan J. Taliercio, DO, George Thomas, MD, Georges N. Nakhoul, MD, MEd, Tushar J. Vachharajani, MD and Ali Mehdi, MD, MEd
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 59-63; DOI: https://doi.org/10.3949/ccjm.88a.20190

    Randomized controlled trials of these new agents had positive outcomes.

  • Trials and tribulations of testosterone therapy in women: Importance of adhering to the evidence
    Juliana M. Kling, MD, MPH, NCMP, FACP and Sharon J. Parish, MD
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 44-46; DOI: https://doi.org/10.3949/ccjm.88a.20195

    Testosterone should not be touted for outcomes that are not supported by data.

  • Prostate cancer: To screen or not to screen? The question is complicated
    Timothy Gilligan, MD
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 17-18; DOI: https://doi.org/10.3949/ccjm.88a.20192

    Prostate cancer screening is controversial due to the complexity of harms and benefits.

  • The HPV vaccine: Understanding and addressing barriers to vaccination
    Pelin Batur, MD
    Cleveland Clinic Journal of Medicine September 2020, 87 (9) 545-548; DOI: https://doi.org/10.3949/ccjm.87a.20082

    Key steps include optimizing clinician-patient communication.

  • Cardiac troponin testing: Goodbye, ‘troponinemia’
    Anirudh Kumar, MD, Divyang R. Patel, MD and Venugopal Menon, MD
    Cleveland Clinic Journal of Medicine August 2020, 87 (8) 483-484; DOI: https://doi.org/10.3949/ccjm.87a.20013

    Any troponin elevation is prognostically important; dismissing it as “troponinemia” is no longer a viable strategy.

  • Device-based therapies for resistant hypertension in chronic kidney disease: The continuing quest for a cure
    George Thomas, MD
    Cleveland Clinic Journal of Medicine July 2020, 87 (7) 444-447; DOI: https://doi.org/10.3949/ccjm.87a.20092

    Device-based therapies have shown promise, but many points still need clarification.

  • Denosumab cessation
    Chad L. Deal, MD
    Cleveland Clinic Journal of Medicine June 2020, 87 (6) 339-341; DOI: https://doi.org/10.3949/ccjm.87a.20040

    Bone loss is rapid if patients miss injections. Clinicians can take extra measures to ensure patients get appropriate treatment.

  • Preventing migraine: The old and the new
    Glen D. Solomon, MD
    Cleveland Clinic Journal of Medicine April 2020, 87 (4) 219-221; DOI: https://doi.org/10.3949/ccjm.87a.19147

    Roughly half of patients taking any preventive medication have a 50% reduction in migraine frequency.

  • Atypical anorexia nervosa can be just as bad
    Neville H. Golden, MD and Philip S. Mehler, MD
    Cleveland Clinic Journal of Medicine March 2020, 87 (3) 172-174; DOI: https://doi.org/10.3949/ccjm.87a.19146

    Eating disorders can occur in patients with a wide variety of weights.

  • Gene therapy in sickle cell disease: Possible utility and impact
    Susanna A. Curtis, MD, MS and Niketa C. Shah, MD
    Cleveland Clinic Journal of Medicine January 2020, 87 (1) 28-29; DOI: https://doi.org/10.3949/ccjm.87a.19124

    CRISPR-Cas9 makes it possible to edit the patient’s own genes, but questions remain.

Pages